Program
GSK3862995B
A development code.
In GlaxoSmithKline's pipeline, Long acting anti-interleukin 33 (IL33) antibody
. Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Bronchiectasis, led by GlaxoSmithKline.
Furthest: phase 2, since Sep 23, 20255 company-led studies, 4 open or runningNext primary completion: Dec 16, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 54 open or running | phase 2since Sep 23, 2025 | Nov 26, 2023 | Dec 16, 2026phase 1 · NCT06154837 |
- Named in GlaxoSmithKline’s own pipeline as
GSK3862995
, phase 2, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 26, 2023First study: phase 1 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT06154837 · 127 enrolled · United States, Germany, United Kingdom
- May 13, 2025Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT06979518 · 30 enrolled · United States
- Sep 23, 2025Phase 2 study in BronchiectasisNCT07201051 · 363 planned · United States, Argentina, China and more
- Aug 24, 2026Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT07789899 · 24 planned · United Kingdom
- Oct 29, 2026Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07915791 · 279 planned
Ahead
- Dec 16, 2026Primary completion: phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT06154837
- May 4, 2027Primary completion: phase 2 study in BronchiectasisNCT07201051
- Sep 7, 2027Primary completion: phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT07789899
- Mar 16, 2029Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07915791
TargetBeta
“Long acting anti-interleukin 33 (IL33) antibody”the company's pipeline, read by Claude · source
Other programs on IL33
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| itepekimabrule | Sanofi | phase 3 | 17 |
| ompekimig | Pfizer | phase 2 | 3 |
| HXN-1013rule | Helixon Biotechnology (Suzhou) | phase 1 | 1 |
| HY6725rule | Newsoara Biopharma | phase 1 | 1 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07915791Pulmonary Disease, Chronic Obstructive | 2 | Not yet recruiting | Mar 16, 2029 | 279 |
| NCT07789899Pulmonary Disease, Chronic Obstructive · United Kingdom | 1 | Recruiting | Sep 7, 2027 | 24 |
| NCT07201051Bronchiectasis · United States, Argentina, China and more | 2 | Recruiting | May 4, 2027 | 363 |
| NCT06979518Pulmonary Disease, Chronic Obstructive · United States | 1 | Completed | Apr 22, 2026 | 30 |
| NCT06154837Pulmonary Disease, Chronic Obstructive · United States, Germany, United Kingdom | 1 | Active, not recruiting | Dec 16, 2026 | 127 |
How it is read
Names in the registry
- “GSK3862995B”, 5 entries
Codes read as this program: GSK3862995B.
Conditions, from the studies’ own filings
- Pulmonary Disease, Chronic Obstructive, 4 studies
- Bronchiectasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.